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Precancerous lesions of the cervix 
— aetiology, classification, diagnosis, 
prevention
ABSTRACT
The present review introduces the aetiology and classification o f cervical p recancers. The principles o f di-
agnosis based on colposcopy are reviewed. The indications for colposcopy and targeted biopsy are steps 
in the diagnostic process of cervical precancers. Prophylaxis of these diseases prevents cervical cancer as 
high-grade precancerous lesions represent a direct precursor to cervical cancer. The basics of primary and 
secondary prevention, the types of screening, and the behaviour of the already-alerted patients after different 
screenings are presented.
Key words: colposcopy, targeted biopsy, cervical precancerous lesions, cytosmear, HPV vaccines, HPV 
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Characteristics and classification of 
cervical precancers
Cervical cancer (CC) has precursors — cell changes 
can be detected by the so-called screening methods [1, 2].
These cellular changes are called dysplasia or CIN 
— cervical intraepithelial neoplasia (Europe), and SIL 
— squamous intraepithelial lesion (Bethesda, USA). 
They are classified as:
 — mild dysplasia: CIN1/LGSIL (low-grade SIL);
 — severe dysplasia: CIN2, CIN3 / HGSIL (high grade 
SIL) [1, 2].
Aetiology
Human papillomavirus (HPV) role in cervical 
carcinogenesis
HPV is one of the main aetiological agents for de-
veloping cervical precancers and cervical cancer (CC). 
Low-risk and high-risk HPV strains lead to low-grade 
dysplasia (CIN1/LGSIL1). Only high-risk HPV strains 
are responsible for disease progression [3].
There are over 100 different HPV subtypes. Only 
high-risk strains are responsible for cervical carcinogen-
esis (HPV  16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 56, 58, 
59, 66) and belong to class I carcinogens. HPV 16 and 
18 are the two main subtypes associated with cervical 
cancer. The other important strains vary regionally. HPV 
16 contributes to 50–55% of the cases of invasive cervical 
cancer. Collectively, HPV 16 and 18 are responsible for 
approx. 70% of cervical cancer. This infection is associ-
ated with certain risk factors [4, 5].
Risk factors for HPV infection:
 — sexual behaviour (promiscuity, low sexual culture);
 — smoking;
 — eating habits;
 — immunosuppression.
The so-called asymptomatic HPV carriers happen 
in 5–20% of sexually active women of reproductive 
age. HPV infection is very often reversible. About 90% 
Oncology in Clinical Practice  
DOI: 10.5603/OCP.2021.0027 
Copyright © 2021 Via Medica 
ISSN 2450–1654
e-ISSN 2450–6478
This article is available in open access under Creative Common Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, allowing to 
download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.
Received: 24.04.2021 Accepted: 11.06.2021 Early publication date: 08.10.2021
177
Yavor Kornovski et al., Precancerous lesions of the cervix
of HPV infections can regress spontaneously within 
24–36 months [3, 5].
The incidence of HPV infection is 7% for the age range 
20–25 years and less than 2% for women over 30 years of 
age. Persistent infection with high-risk HPV strains (16, 
18) progresses to HGSIL and cervical cancer. It has been
established that HPV infection expresses 2 oncogenes
(oncoproteins) — E6 and E7, which in turn inhibit tu-
mour suppressor genes (p53, retinoblastoma rb), causing
uncontrolled cell division. Specific indistinct co-factors act
as triggers since not every persistent infection with high-risk 
papillomavirus strains leads to cancer. The transforma-
tional period is inconsistent in different patients [3–5].
Diagnosis of cervical precancers
Histological diagnosis of these lesions is performed 
in two ways:
1. Colposcopy and targeted biopsy (pinch biopsy under 
colposcopic control);
2. See-and-treat strategy: in case of inconsistency
between cytology (cytologically-signalled patients)
and negative/unsatisfactory colposcopic evaluation, 
LLETZ (large loop excision of the transformation
zone) is required, i.e., loop excision providing his-
tological material for diagnosis [6, 7].
Colposcopy plays a key role in the diagnosis and
treatment of cervical precancers [8–13].
 — Colposcopy allows for the identification, location 
and outlining of CIN lesions on the cervix, vagina 
and vulva [8].
 — Colposcopy is mandatory for diagnosing and treat-
ment of CIN. It manifests the most susceptive areas 
where a targeted pinch biopsy should be executed [9].
The main indications for colposcopy are [10]:
1. Abnormal cytology;
2. HPV screening-signalled patients;
3. Contact bleeding.
The goals of colposcopy are [12, 13]:
1. To identify the site of pinch biopsy that is mostly
suspected for HGSIL.
2. To establish the condition of the transformation
zone (TZ) and the squamous-cylindrical epithelium 
border. Assessment of (un)satisfactory colposcopy.
3. To exclude the presence of invasive cervical cancer.
Targeted biopsy should always be performed under
colposcopic control. Indications for targeted pinch 
biopsy are:
 — before performing ablation based on colposcopic 
CIN data [14];
 — in case of inconsistency between cytology and col-
poscopic finding [15];
 — for histological verification of atypical colposcopic 
finding (low-grade — Grade 1 and high-grade 
— Grade 2) (Fig. 1, 2) [14–17].
Figure 1. Low-grade Grade1 finding
Figure 2. High-grade Grade2 finding
Figure 3. Low-grade atypia with visible borders of the lesion
TZ condition
A satisfactory (adequate) colposcopic examination is one 
in which the squamous-cylindrical epithelium border and 
the borderlines of the atypical epithelium are clearly visible. 
Unsatisfactory (inadequate) colposcopy is the one with an 
unclear squamous-cylindrical epithelium border and/or an 
unclear distal border of an atypical lesion [8–13] (Fig. 3, 4).
Colposcopic signs for early invasion [10]
1. Size of the lesion: the larger the lesion, especially if
it covers the vaginal fornix, the more suspicious of
microinvasion it is.
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5. Raised edges — “mountain range”.
6. Vascular atypia — different in calibre, direction,
size.
7. Intense whitening (“chalk whitening”) after ace-
tic acid.
Prevention of cervical precancerous 
lesions (cervical cancer prophylaxis). 
Primary and secondary prevention
Primary prevention of cervical cancer
Cervical cancer has a clear etiological factor: HPV 
high-risk oncogenic strains. Exposure prevention to 
this factor is called primary prophylaxis achieved with 
vaccines against specific human papillomavirus strain. 
In Bulgaria, there are currently two vaccines available: 
Silgard — effective against strains 6, 11, 16, 18, and 
Cervarix — against strains 16, 18. By 2014, there have 
been 47 million vaccinated girls, according to WHO 
and the Global Advisory Committee on Vaccine Safety 
(GACVS). The safety of 175 million doses has been 
confirmed till 2013. As of 2014, GACVS has issued no 
comments on the vaccine’s safety. No increased risk of 
autoimmune diseases, including multiple sclerosis, has 
been monitored as of 2015/16. More than 120 countries 
have approved HPV vaccines as part of their immuniza-
tion calendars. The only recommendation is 15 minutes 
of follow-up after vaccination due to possible syncope 
after injection [18, 19].
Secondary prevention of cervical cancer
Detection of the so-called cervical cancer precur-
sors — high-grade lesions CIN (2–3)/HGSIL and pre-
venting their progression to invasive cancer through 
screening, behaviour signalling, follow-up, and possible 
treatment. Screening methods (screening programs) 
for secondary prevention have been developed [20, 21]. 
There are two types of cervical screening: organized 
(population-wide), which targets certain groups (by age 
and frequency/interval of studies), and opportunistic, 
which is not comprehensive and does not meet the 
criteria for a screening program. It is applied during 
a visit to a gynaecologist [20, 21].
Criteria for organized screening [20, 21]:
1. Mass screening: includes a specific target population
during a specific screening interval.
2. Quality follow-up care and treatment of screen-
ing-positive women.
3. Effective communication between the individual
components of the screening program (from screen-
ing to diagnosis and treatment).
4. High-quality screening tests, diagnostic assessment, 
treatment and follow-up care.
5. Adequate infrastructure, trained medical staff.
6. Financial resources.
Types of cervical screening
 — HPV high-risk strains screening.
 — Cytological — conventional and LBC (liquid-based 
cytology) [20].
HPV screening
It is characterized by high sensitivity: negative predic-
tive value (NPV) — sensitivity to CIN3 > 95%, and low 
specificity — positive predictive value (PPV) [22]. The 
specificity (PPV) of HPV is lower than that of cytology 
(Cuzack 2006, Tab. 1).
Randomized trials have reached the following con-
clusions regarding HPV screening [22, 23]:
 — HPV screening is a more productive and cost-effective 
method for reducing the incidence of cervical cancer. 
 — HPV screening allows for extended screening inter-
vals but requires a high level of organization.
 — HPV-positive patients undergo cytological screening.
 — HPV screening is only suitable for women over 
30 years of age.
 — The integration of organized HPV screening and 
vaccination will make cervical cancer a rare disease.
The European guidelines for quality cervical cancer 
screening provide the following recommendations for 
primary HPV screening [22–24]:
Figure 4. Unclear distal border of the atypical area
Table 1. Sensitivity and specificity according to the cervical 
screening method 
Method Sensitivity [%] Specificity [%]
Cytology 53.0 96.3
HPV typing 96.1 90.7
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1. HPV screening (with oncogenic HPV tests) can be 
applied as organized (population) screening
2. The so-called Co-testing (HPV + cytology) should 
be avoided.
3. Only one primary screening method (HPV or cytol-
ogy) should be used for the relevant age groups.
4. Routine primary HPV screening may begin over 
35 years of age and not earlier than 30 years.
5. There is insufficient evidence of the applicability 
of this screening for the age group of 30–35 years.
6. HPV screening stops at 60–65 years, and the cy-
tological screening provided that the last result 
is negative.
7. Cytological screening is used beyond the age range 
of primary HPV screening.
8. The screening interval after the HPV (–) test is 
between 5 and 10 years.
Behaviour and follow-up of HPV-alerted 
patients
There are three risk groups [25]:
A.  Patients positive for HPV 16, 33 strains. 
 The assessment is for very high risk; colposcopy 
is required, and readiness for treatment of CIN.
B.  Patients positive for HPV 31, 18, 52, 35, 58 strains.
 The assessment is for high risk and requires colpos-
copy; HPV 18 causes endocervical lesions.
C.  Patients positive for HPV 51, 68, 45, 39, 66, 56, 
59 types.
The assessment is for intermediate-risk, and a new 
HPV test after one year is recommended.
In some countries, this type of screening is used 
for the first time [26]. In the United States, HPV 
positives for HPV16, 18 are referred for colposcopy. 
Positive for other high-risk HPV strains are subject to 
cytological examination. Colposcopy is recommended 
in cytologically-signalled patients. If the smear test is 
negative, new cytology is performed after one year. 
HPV-negative patients are subject to a new test in five 
years. In Belgium and the Netherlands, HPV negatives 
are subject to a new test in five years. The positives are 
smeared: if it is smear-positive, patients are referred for 
colposcopy; if the cytology finding is normal, the test is 
repeated after one year. If it is still normal, the woman is 
subject to HPV screening after five years [26]. Similar to 
the above is the screening system in Italy, where instead 
of repeated cytology, an HPV test is performed.
HPV screening challenges
The HPV test is characterized by high sensitiv-
ity (NPV) but low specificity. Increasing specificity 
can be achieved by testing for HPV types (16, 18, 33) 
and improving cytology by dual-stain cytology testing 
for p16 and Ki 67 — this study is a predictor of CIN 
2–3. Testing for oncoproteins E6, E7 also complements 
the screening and manifests that persistent viral infection 
leads to changes in the cellular regulatory cycle [27, 28].
The combination of vaccination and HPV screening is 
fundamental to cervical cancer eradication programs [29, 30].
HPV vaccination programs include girls aged 12 to 
14 years and provide 100% effectiveness against vac-
cine strains (if vaccinated before infection). In some 
countries, boys are also vaccinated [29].
Post-vaccination screening provides for an extended 
screening interval. In the future, patients will be able 




There are three cytological screening systems used 
in practice [31]:
1. Papanicolaou system or PAP smear test.
2. The Bethesda system (TBS) — 2001, 2014.
3. The British Society for Clinical Cytology (BSCC) 
classification: used in the UK. According to this 
system, cellular changes are defined as:
 — borderline nuclear changes — BNC (HPV atypia 
— koilocytosis);
 — mild changes — corresponds to CIN1;
 — moderate changes — corresponds to CIN2;
 — severe changes — corresponds to CIN3.
The Bethesda system grades cellular changes as 
follows (2014):
1. Non-neoplastic cells.
2. Epithelial cells abnormality — these are cytolog-
ically-signalled patients. The changes can affect 
squamous cells and are described as atypical squa-
mous cells of undetermined significance (ASCUS); 
atypical squamous cells cannot exclude high-grade 
squamous intraepithelial lesion (ASC-H); LGSIL, 
HGSIL; and glandular cells.
Abnormal Cytosmear Recommendations
Abnormal Cytosmear Recommendations of the 
American Society for Colposcopy and Cervical Pathol-
ogy (ASCCP) [32]:
In cases of ASCUS (atypical squamous cells of unde-
termined significance) or BNA (borderline nuclear ab-
normality), three lines of behaviour are recommended:
1. Repeat the smear after six months
— if negative, repeat after six months;
— in case of two negative results, return to rou-
tine observation;
— if positive (ASCUS, borderline), the patient is 
referred for colposcopy.
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2. Immediate colposcopy
— in the case of normal colposcopy results — cytol-
ogy after one year.
3. HPV (DNA) triage:
— HPV positive results — colposcopy;
— HPV negative results — repeated cytology after 
one year.
In the case of ASC-H (atypical squamous cells — can 
not exclude high-grade squamous intraepithelial lesion), 
the patient is referred for colposcopy:
 — if the colposcopy result is negative — a new smear 
test is recommended;
 — if the colposcopy and the new cytology are negative 
cytology after six months is recommended.
In the case of LGSIL/CIN1 (mild dyskaryosis), col-
poscopy is recommended.
 — If the colposcopy result is normal — a new cytology 
test and/or HPV test is recommended.
 — In the case of HGSIL result, the patient is referred 
for colposcopy and biopsy.
 — If the colposcopy is satisfactory and the biopsy does 
not detect HGSIL, revision of cytology and histology 
is recommended. If HGSIL is detected — treatment 
with LLETZ is recommended.
 — If the colposcopy is unsatisfactory, it is recommend-
ed to perform LLETZ (see-and-treat protocol). 
Summary
Concerning terminology, CIN1 is classified as 
a low-grade squamous intraepithelial lesion (LGSIL) 
and CIN2/3 as a high-grade squamous intraepithelial 
lesion (HGSIL). High-risk HPVs (16, 18, 33) are re-
sponsible for the progression of the carcinogenesis pro-
cess. Primary prophylaxis (vaccination) is highly effec-
tive. Secondary prophylaxis is based on the application of 
screening systems (HPV high-risk strains and cytology). 
In screening-positive women, colposcopy is most often 
performed with or without a biopsy. The diagnosis of 
precancerous lesions is histological after colposcopic 
evaluation (targeted biopsy or see-and-treat protocol).
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